Similarly, in T cell-driven graft-versus-host disease (GVHD), FXR agonism exacerbated mortality, while T cell-specific FXR deletion or UDCA administration (again exhibiting FXR antagonistic properties) improved outcomes (88). The gene discussed is NR1H4; the disease is graft versus host disease.